Rome, Nov 9. (Adnkronos Health) – Faster and more equitable access to medicines, simpler rules, system sustainability, and greater attractiveness for investments. These are some of the challenges at the heart of the delegated bill for the reform and reorganization of pharmaceutical legislation, approved in first reading by the Senate and now under examination by the Chamber of Deputies, which outlines the path towards the future Unified Text. A strategic regulatory review for the National Health Service and for the country’s competitiveness, called to accompany innovation and respond to citizens’ needs. “The goal is not only to simplify and reorganize existing legislation, but to ensure that therapeutic innovation, the availability of medicines, and healthcare services can reach citizens more quickly, uniformly, and effectively, regardless of their place of residence.” On these issues, the event ‘The Future of Pharmaceutical Legislation. A System Vision’ focused today in Rome, bringing together institutions, the medical-scientific community, industry, drug distribution, and citizen representatives to contribute to the discussion on the reform.
“The Unified Text of pharmaceutical legislation represents a reform awaited for decades, necessary to overcome the regulatory fragmentation accumulated over time and to provide the country with a more modern, organic, and coherent regulatory framework – declared the Undersecretary of Health Marcello Gemmato – The objective is to create the conditions to guarantee increasingly rapid access to therapeutic innovations, support the competitiveness of a strategic sector for the national economy, and strengthen Italy’s ability to attract research and investments. It is a challenge that requires the contribution of all system actors, always keeping the citizens’ right to health at the center.”
A reform path that cannot disregard the contribution of science and the experience gained in the field by those who are committed every day to patient care. “Pharmaceutical reform is not just a bureaucratic or commercial challenge, but a social change that will impact the lives of millions of citizens. The decisions made today will guide tomorrow’s medicine – explained Loreto Gesualdo, president of Fism (Federation of Italian Medical-Scientific Societies) – For this reason, Scientific Societies cannot limit themselves to being mere spectators: we are ready to offer national and European institutions our know-how to ensure that the new legislation is guided by objective and rigorous scientific method and patient centrality.” If patient centrality represents the compass of the reform, the system’s ability to support innovation, research, and investments is an essential condition. Hence the widely shared request for simple, stable, and predictable rules, capable of strengthening the competitiveness of the Italian pharmaceutical sector.